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Letter to the Editor of European Journal of Nuclear Medicine and Molecular Imaging 
All that Glitters is not Gold – new reconstruction methods using Deauville criteria for patient reporting 
Sally Barrington 1 Tom Sulkin 2 Adam Forbes 3 and Peter Johnson 4 
1 KCL and Guy’s and St Thomas’ PET Centre, School of Biomedical Engineering and Imaging Sciences, 
King’s College London, 2  Clinical Imaging Department, Royal Cornwall Hospital 3 Haematology 
Department, Royal Cornwall Hospital 4 Cancer Research UK Centre, University of Southampton  
Abstract 
New reconstruction methods can improve lesion detection by improving spatial resolution and reducing 
image noise.  Such methods can result in an increase in lesional uptake, whilst leaving uptake in 
reference regions such as the mediastinum and liver relatively unaffected. This may alter the 
interpretation of response assessment in patients with lymphoma using the Deauville criteria. 
We report how the use of newer reconstruction methods may alter patient management by affecting 
decisions to de-escalate or escalate treatment using a PET guided approach and urge caution before 
adopting these newer reconstruction methods in isolation into routine practice. 
 
 
Dear Sir 
We would like to highlight the importance of using EANM Research Ltd (EARL) compliant reconstructions 
for assessment of lymphoma response using the Deauville criteria [1] in clinical practice.   
The recent review in this journal by Aide et al reported that only 38% of EARL accredited centres who 
responded to a survey, were systematically using EARL compliant reconstructions for quantification [2].  
This was despite 88% of these centres being research active.   
We recently observed an increase in the number of patients with interim PET ‘positive’ scans being 
treated by a regional haematology multidisciplinary team (MDT) for Hodgkin lymphoma in the UK.  This 
coincided with the adoption of Q.Clear (GE) reconstruction [3] for reporting scans at some PET centres.   
An independent review of PET-CT scans from eight of these patients with advanced stage disease 
planned for treatment using a PET response adapted approach [4] was undertaken at the request of the 
MDT.  Baseline and interim scans after 2 cycles of doxorubicin, bleomycin, vinblastine and dacarbazine 
(ABVD) chemotherapy were reviewed using standard ordered subset expectation maximisation (OSEM) 
VPHD and Q.Clear reconstructions.  The interim response scans had been reported as Deauville score 4 
for each of the eight patient cases. 
For five patient scans, the assessment of the independent reviewer was the same as the local reporter, 
irrespective of the reconstruction method applied.  For two patients, the independent reviewer 
considered the interim scan to demonstrate a complete metabolic response with Deauville scores of 2 
and 3 respectively using OSEM reconstruction.  When the Q.Clear reconstruction was applied however, 
small areas of residual uptake in the right neck in one patient and in a lung mass in the second patient 
showed increased uptake compared to OSEM reconstruction.  This increased uptake using Q.Clear at the 
site of initial disease was greater than normal liver, i.e.  Deauville score 4.  One of these patients 
received escalated treatment, switching from planned AVD chemotherapy to bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisolone (escalated BEACOPP) 
chemotherapy on the basis of the report.   
In a further patient scan, the difference of opinion between reporters was unrelated to the 
reconstruction but rather to the interpretation of nodal uptake, which was higher than liver using either 
reconstruction method.  The initial reporter considered uptake in a right cervical level II node to 
represent an involved node, whereas the independent reviewer considered it to be an inflammatory 
node, as the node did not demonstrate FDG uptake at baseline and all other sites of baseline disease 
had resolved. 
New image reconstruction methods using resolution or point spread function (PSF) modelling, such as 
Sharp IR (GE)[5] and HD (Siemens)[6] and Bayesian penalised likelihood techniques, e.g. Q.Clear (GE)[3] 
represent advances in image reconstruction [7]. These methods improve lesion spatial resolution and 
reduce noise [8] particularly for small lesions and are more likely to be quantitatively accurate than 
OSEM [9].  Q.Clear has been reported to lead to improved sensitivity, albeit at the expense of reduced 
specificity in the detection of malignancy in lung nodules [10], mediastinal nodes in lung cancer [11] and 
liver metastases from colorectal cancer [12]. 
However, as uptake in reference ‘normal’ regions of the mediastinum and liver is largely unaffected [13, 
14] the use of these reconstructions can lead to different scoring using the Deauville criteria and 
interpretation of response assessment for patients with lymphoma using the Lugano Classification [15]. 
This may alter patient management by affecting decisions to de-escalate or escalate treatment using a 
PET guided approach, as with the patient reported here.  Prospective trials that have validated PET-
guided approaches in lymphoma used quality assured data with OSEM reconstruction [4, 16-18]. 
We urge reporters not to use new reconstruction algorithms in isolation for response assessment [2]. If 
reporters prefer to use new algorithms for optimal lesion detection, a second dataset with OSEM 
reconstruction, should be used alongside to provide a Deauville score.  We recognise that a single 
dataset which visually enhances lesion detection, using PSF, but provides similar quantification has been 
developed (eq.PET, Siemens) [19] which attempts to overcome the requirement to view two image 
datasets.  It may however lead the reporter to select a different ‘hottest’ residual lesion for 
quantification purposes compared to OSEM.   
Therefore whilst we accept that newer reconstruction techniques may improve diagnosis, we consider 
that further assessment is required and suggest validation in lymphoma patients before adoption in 
routine practice.  In conclusion, ‘All that Glitters is not Gold’ and reporters should consider the potential 
clinical impact of using new reconstruction methods with the Deauville criteria. 
Yours faithfully 
Sally Barrington   
Tom Sulkin  
Adam Forbes  
Peter Johnson  
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